Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Tanja D de Gruijl"'
Autor:
Chris Dickhoff, Suresh Senan, Famke L. Schneiders, Joris Veltman, Sayed Hashemi, Johannes M. A. Daniels, Marieke Fransen, David J. Heineman, Teodora Radonic, Peter M. van de Ven, Imke H. Bartelink, Lilian J. Meijboom, Juan J. Garcia-Vallejo, Daniela E. Oprea-Lager, Tanja D. de Gruijl, Idris Bahce
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
Abstract Background The likelihood of a tumor recurrence in patients with T3-4N0–1 non-small cell lung cancer following multimodality treatment remains substantial, mainly due distant metastases. As pathological complete responses (pCR) in resected
Externí odkaz:
https://doaj.org/article/b810006f73e5465ca6860f5c7acd4a6c
Autor:
Robert Olson, Lindsay Mathews, Mitchell Liu, Devin Schellenberg, Benjamin Mou, Tanya Berrang, Stephen Harrow, Rohann J. M. Correa, Vasudeva Bhat, Howard Pai, Islam Mohamed, Stacy Miller, Famke Schneiders, Joanna Laba, Derek Wilke, Sashendra Senthi, Alexander V. Louie, Anand Swaminath, Anthony Chalmers, Stewart Gaede, Andrew Warner, Tanja D. de Gruijl, Alison Allan, David A. Palma
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-12 (2020)
Abstract Background A recent randomized phase II trial evaluated stereotactic ablative radiotherapy (SABR) in a group of patients with a small burden of oligometastatic disease (mostly with 1–3 metastatic lesions), and found that SABR was associate
Externí odkaz:
https://doaj.org/article/2164cc83a76d4a73a0be273fbb56cec5
Autor:
David A. Palma, Robert Olson, Stephen Harrow, Rohann J. M. Correa, Famke Schneiders, Cornelis J. A. Haasbeek, George B. Rodrigues, Michael Lock, Brian P. Yaremko, Glenn S. Bauman, Belal Ahmad, Devin Schellenberg, Mitchell Liu, Stewart Gaede, Joanna Laba, Liam Mulroy, Sashendra Senthi, Alexander V. Louie, Anand Swaminath, Anthony Chalmers, Andrew Warner, Ben J. Slotman, Tanja D. de Gruijl, Alison Allan, Suresh Senan
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-15 (2019)
Abstract Background Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local cont
Externí odkaz:
https://doaj.org/article/311e255a7ed5440d80c65380d5f3034c